Tricalcium phosphate nanoparticles enable rapid purification, increase transduction kinetics, and modify the tropism of mammalian viruses

Biotechnology and Bioengineering

Volumn 102, Issue 4, 2009, Pages 1197-1208

  Dreesen, Imke A J ^a   Lüchinger, Norman A ^a   Stark, Wendelin J ^a   Fussenegger, Martin ^a  

^a ETH ZURICH   (Switzerland)

Author keywords

Adeno associated virus type 2 (AAV); Adenovirus type 5; Amorphous tricalcium phosphate nanoparti cles (ATCP); Gene therapy; Human immunodeficiency virus type 1 (HIV 1); Murine leukemia virus (MLV)

Indexed keywords

ADENO-ASSOCIATED VIRUS TYPE 2 (AAV); ADENOVIRUS TYPE 5; AMORPHOUS TRICALCIUM PHOSPHATE NANOPARTI-CLES (ATCP); GENE THERAPY; HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1); MURINE LEUKEMIA VIRUS (MLV);

ANIMAL CELL CULTURE; BACTERIOPHAGES; GENE TRANSFER; INTERNET; MAMMALS; NANOPARTICLES; PURIFICATION; THERMAL EXPANSION;

CELL CULTURE;

ADENOVIRUS VECTOR; CALCIUM PHOSPHATE; GREEN FLUORESCENT PROTEIN; LENTIVIRUS VECTOR; NANOCARRIER; PARVOVIRUS VECTOR; YELLOW FLUORESCENT PROTEIN; NANOPARTICLE;

ADENO ASSOCIATED VIRUS; ADENOVIRUS 5; ANIMAL CELL; ARTICLE; CELL STRAIN 3T3; CELL STRAIN HEK293; CHO CELL; CONTROLLED STUDY; DRUG PURIFICATION; FLUORESCENCE MICROSCOPY; GENE TARGETING; HELA CELL; HUMAN; HUMAN CELL; LENTIVIRINAE; MOUSE; MURINE LEUKEMIA VIRUS; NONHUMAN; SCANNING ELECTRON MICROSCOPY; VIRAL GENE DELIVERY SYSTEM; VIRUS CELL INTERACTION; VIRUS PARTICLE; ADENOVIRUS; ANIMAL; CELL LINE; GENETIC TRANSDUCTION; ISOLATION AND PURIFICATION; MAMMAL; PHYSIOLOGY;

ADENO-ASSOCIATED VIRUS - 2; HUMAN ADENOVIRUS TYPE 5; HUMAN IMMUNODEFICIENCY VIRUS 1; MAMMALIA; MURINE LEUKEMIA VIRUS;

ADENOVIRIDAE; ANIMALS; CALCIUM PHOSPHATES; CELL LINE; DEPENDOVIRUS; HUMANS; LENTIVIRUS; MAMMALS; NANOPARTICLES; TRANSDUCTION, GENETIC;

EID: 60549106185     PISSN: 00063592     EISSN: 10970290     Source Type: Journal    
DOI: 10.1002/bit.22157     Document Type: Article

References (38)

1. Aghi M, Martuza RL. 2005. Oncolytic viral therapies-The clinical experience. Oncogene 24(52):7802-7816.
2. Andreadis ST, Roth CM, Le Doux JM, Morgan JR, Yarmush ML. 1999. Large-scale processing of recombinant retroviruses for gene therapy. Biotechnol Prog 15(1):1-11.
3. Billinge SJL, Levin I. 2007. The problem with determining atomic structure at the nanoscale. Science 316(5832):1698-1698.
4. Bonifazi D, Kiebele A, Stohr M, Cheng FY, Jung T, Diederich F, Spillmann H. 2007. Supramolecular nanostructuring of silver surfaces via self-assembly of [60]fullerene and porphyrin modules. Adv Funct Mater 17(7):1051-1062.
5. Brunner TJ, Wick P, Manser P, Spohn P, Grass RN, Limbach LK, Bruinink A, Stark WJ. 2006. In vitro cytotoxicity of oxide nanoparticles: Comparison to asbestos, silica and the effect of particle solubility. Environ Sci Technol 40(14):4373-4381.
6. Bushman FD. 2003. Targeting survival: Integration site selection by retro-viruses and LTR-retrotransposons. Cell 115(2):135-138.
7. Cavazzana-Calvo M, Thrasher A, Mavilio F. 2004. The future of gene therapy. Nature 427(6977):779-781.
8. Edelstein ML, Abedi MR, Wixon J. 2007. Gene therapy clinical trials worldwide to 2007-An update. J Gene Med 9(10):833-842.
9. Fischer A, Hacein-Bey-Abina S, Cavazzana-Calvo M. 2004. Gene therapy of children with X-linked severe combined immune deficiency: Efficiency and complications. Med Sci (Paris) 20(1):115-117.
10. Fluri DA, Baba MD, Fussenegger M. 2007. Adeno-associated viral vectors engineered for macrolide-adjustable transgene expression in mammalian cells and mice. BMC Biotechnol 7:75.
11. Gonzalez-Nicolini V, Fussenegger M. 2005. A novel binary adenovirus-based dual-regulated expression system for independent transcription control of two different transgenes. J Gene Med 7(12):1573-1585.
12. Green AP, Huang JJ, Scott MO, Kierstead TD, Beaupre I, Gao GP, Wilson JM. 2002. A new scalable method for the purification of recombinant adenovirus vectors. Hum Gene Ther 13(16):1921-1934.
13. Grimm D, Kay MA, Kleinschmidt JA. 2003. Helper virus-free, optically controllable, and two-plasmid-based production of adeno-associated virus vectors of serotypes 1 to 6. Mol Ther 7(6):839-850.
14. Hou D, Xie C, Huang K, Zhu C. 2003. The production and characteristics of solid lipid nanoparticles (SLNs). Biomaterials 24(10):1781-1785.
15. Kamen A, Henry O. 2004. Development and optimization ofan adenovirus production process. J Gene Med 6(Suppl 1):S184-S192.
16. Kohane DS. 2007. Microparticles and nanoparticles for drug delivery. Biotechnol Bioeng 96(2):203-209.
17. Landazuri N, Le Doux JM. 2004. Complexation ofretroviruses with charged polymers enhances gene transfer by increasing the rate that viruses are delivered to cells. J Gene Med 6(12):1304-1319.
18. Le Doux JM, Landazuri N, Yarmush ML, Morgan JR. 2001. Complexation of retrovirus with cationic and anionic polymers increases the efficiency of gene transfer. Hum Gene Ther 12(13):1611-1621.
19. Limbach LK, Li Y, Grass RN, Brunner TJ, Hintermann MA, Muller M, Gunther D, Stark WJ. 2005. Oxide nanoparticle uptake in human lung fibroblasts: Effect of particle size, agglomeration and diffusion at low concentration. Environ Sci Technol 39(23):9370-9376.
20. Link N, Brunner TJ, Dreesen IA, Stark WJ, Fussenegger M. 2007. Inorganic nanoparticles for transfection of mammalian cells and removal of viruses from aqueous solutions. Biotechnol Bioeng 98(5):1083-1093.
21. Loher S, Stark WJ, Maciejewski M, Baiker A, Pratsinis SE, Reichardt D, Maspero F, Krumeich F, Gunther D. 2005. Fluoro-apatite and calcium phosphate nanoparticles by flame synthesis. Chem Mater 17(1): 36-42.
22. McTaggart S, Al-Rubeai M. 2002. Retroviral vectors for human gene delivery. Biotechnol Adv 20(1):1-31.
23. Merten OW. 2004. State-of-the-art of the production of retroviral vectors. J Gene Med 6(Suppl 1):S105-S124.
24. Mitta B, Rimann M, Ehrengruber MU, Ehrbar M, Djonov V, Kelm J, Fussenegger M. 2002. Advanced modular self-inactivating lentiviral expression vectors for multigene interventions in mammalian cells and in vivo transduction. Nucleic Acids Res 30(21):e113.
25. Morenweiser R. 2005. Downstream processing ofviral vectors and vaccines. Gene Ther 12(Suppl 1):S103-S110.
26. Murthy SK. 2007. Nanoparticles in modern medicine: State of the art and future challenges. Int J Nanomed 2(2):129-141.
27. Patwardhan SV, Mukherjee N, Durstock MF, Chiang LY, Clarson SJ. 2002. Synthesis of C-60 fullerene-silica hybrid nano structures. J Inorg Organometal Polym 12(1-2):49-55.
28. Pham L, Ye H, Cosset FL, Russell SJ, Peng KW. 2001. Concentration of viral vectors by co-precipitation with calcium phosphate. J Gene Med 3(2): 188-194.
29. Reiser J. 2000. Production and concentration of pseudotyped HIV-1-based gene transfer vectors. Gene Ther 7(11):910-913.
30. Rice E. 1998. The human genome project and gene therapy: A genetic counselor's perspective. J Perinat Neonatal Nurs 12(3):16-25.
31. Rocconi RP, Numnum TM, Stoff-Khalili M, Makhija S, Alvarez RD, Curiel DT. 2005. Targeted gene therapy for ovarian cancer. Curr Gene Ther 5(6):643-653.
32. Segura MM, Kamen A, Garnier A. 2006. Downstream processing of oncoretroviral and lentiviral gene therapy vectors. Biotechnol Adv 24(3):321-337.
33. Stark WJ, Pratsinis SE. 2002. Aerosol flame reactors for manufacture of nanoparticles. Powder Technol 126(2):103-108.
34. Sung JC, Pulliam BL, Edwards DA. 2007. Nanoparticles for drug delivery to the lungs. Trends Biotechnol 25(12):563-570.
35. Wickramasinghe SR, Kalbfuss B, Zimmermann A, Thom V, Reichl U. 2005. Tangential flow microfiltration and ultrafiltration for human influenza A virus concentration and purification. Biotechnol Bioeng 92(2):199-208.
36. Zeimet AG, Marth C. 2003. Why did p53 gene therapy fail in ovarian cancer? Lancet Oncol 4(7):415-422.
37. Zhang L, Gu FX, Chan JM, Wang AZ, Langer RS, Farokhzad OC. 2008. Nanoparticles in medicine: Therapeutic applications and developments. Clin Pharmacol Ther 83(5):761-769.
38. Zufferey R. 2002. Production of lentiviral vectors. Curr Top Microbiol Immunol 261:107-121.